Oryon Cell Therapies Emerges With $42M for Autologous Neuron Replacement Therapy in Parkinson's Disease

on

Oryon Cell Therapies emerged from stealth with $42 million in funding, including a recently closed $21 million Series A, to advance its lead autologous cell therapy for Parkinson's disease13

The company's therapy uses patient-derived blood cells reprogrammed into induced pluripotent stem cells (iPSCs) and then differentiated into dopaminergic neurons that are implanted into the putamen brain region23

Phase 1b/2a trial interim data from five participants showed motor function improvements of 29-62% from baseline at 6-18 months of follow-up, with improvements across gait, rigidity, and bradykinesia12

Dopamine transporter imaging demonstrated marked increases in dopaminergic signaling in transplanted brain regions, with one patient showing more than a five-fold increase in dopamine activity at six months12

The therapy was well-tolerated with no serious adverse events reported, required no immunosuppression, and several patients reduced their levodopa medication doses2

Clinical data were presented on March 21, 2026 at the AD/PD International Conference on Alzheimer's and Parkinson's Diseases in Copenhagen23

The company plans to begin bilateral implantations in a second cohort in the current quarter to test whether bilateral treatment yields further improvements compared to unilateral implants2

Sources:

1. https://www.biospace.com/business/oryon-splashes-onto-parkinsons-scene-with-42m-for-cell-therapy

2. https://www.morningstar.com/news/business-wire/20260323518118/oryon-cell-therapies-reports-phase-1b2a-data-showing-sustained-motor-improvements-in-people-with-parkinsons-disease

3. https://www.businesswire.com/news/home/20260323924704/en/Oryon-Cell-Therapies-Emerges-From-Stealth-Focusing-on-Autologous-Neuron-Replacement-Therapies-for-Parkinsons-Disease-and-Other-Neurodegenerative-Disorders